Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Colorectal Neoplasms 234Carcinoma, Non-Small-Cell Lung 132Breast Neoplasms 121Glioblastoma 88Ovarian Neoplasms 86Carcinoma, Hepatocellular 69Rectal Neoplasms 64Brain Neoplasms 58Lung Neoplasms 55Neoplasm Metastasis 54Neoplasms 52Colonic Neoplasms 50Fallopian Tube Neoplasms 43Glioma 40Carcinoma, Renal Cell 35Gliosarcoma 34Melanoma 26Adenocarcinoma of Lung 26Pancreatic Neoplasms 23Liver Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Recurrence 21Triple Negative Breast Neoplasms 18Kidney Neoplasms 16Endometrial Neoplasms 16Esophageal Neoplasms 15Astrocytoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Temozolomide 5Radiotherapy 2Bevacizumab 2tozuleristide 1olutasidenib 1abemaciclib 1Radiation 1Nivolumab 1Megestrol Acetate 1Lomustine 1Lapatinib 1Irinotecan 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Disulfides 1Cyproheptadine 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Spinal Cord Neoplasms × Bevacizumab × Clear all
NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
35 enrolled 17 charts
CNS

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡